Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study

Barbara Bober, Marek Saracyn, Kornelia Zaręba, Arkadiusz Lubas, Paweł Mazurkiewicz, Ewelina Wilińska, Grzegorz Kamiński

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Neuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progressive and well-differentiated NENs. The aim of the study was to assess early bone marrow and kidney injury after administration of Lutetium-177 or Lutetium-177 combined with Yttrium-90. Thirty-one patients received treatment with [177Lu]Lu-DOTATATE with the activity of 7.4 GBq. Eleven patients received tandem treatment with [90Y]Y-DOTATATE with the activity of 1.85 GBq + [177Lu]Lu-DOTATATE with the activity of 1.85 GBq. After PRRT a significant decrease in leukocyte, neutrophil, and lymphocyte counts was noted. Tandem treatment demonstrated a more marked decrease in white blood cell count compared to Lutetium-177 therapy only. Conversely, no significant influence on glomerular filtration was found in this assessment. However, PRRT triggered acute renal tubule dysfunction, regardless of the treatment type. Regarding the acute complications, PRRT appeared to be a safe modality in the treatment of patients with NEN.

Original languageEnglish
Article number919
JournalJournal of Clinical Medicine
Volume11
Issue number4
DOIs
Publication statusPublished - Feb 2 2022
Externally publishedYes

Keywords

  • Neuroendocrine neoplasm
  • PRRT
  • Treatment of neuroendocrine neoplasm

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study'. Together they form a unique fingerprint.

Cite this